Long-term treatment with growth hormone improves final height in a patientwith Pallister-Hall syndrome

Pallister-Hall syndrome is a disorder of development consisting of hypothal amic hamartoma, pituitary dysfunction, central polydactyly and visceral mal formations. This disorder is inherited as an autosomal dominant trait and i s caused by mutations of the GLI3 gene encoding a zinc finger transcription factor. We describe a case of Pallister-Hall syndrome with growth hormone neurosecretory dysfunction, successfully treated with growth hormone until attainment of final height. We conclude that children with Pallister-Hall s yndrome and short stature be evaluated carefully for spontaneous somatotrop ic function and, if necessary, treated with growth hormone. (C) 2001 Wiley- Liss, Inc.